Nov 8 (Reuters) - Adalta Ltd 1AD.AX :
* Commercialisation agreement with crossbeta biosciences
* Will receive royalties on future revenues from commercialization of aßo-specific shark antibodies as novel therapeutics or diagnostic agents
* Under terms of agreement, crossbeta has been granted an exclusive license to three beta-amyloid oligomer (aßo)-specific shark antibodies
Source text for Eikon: ID:nASX190Qgk
Further company coverage: 1AD.AX